A vaginal nanoformulation of a SphK inhibitor attenuates lipopolysaccharide-induced preterm birth in mice

Kiersten Giusto, Manali Patki, Jagadish Koya, Charles R. Ashby, Swapna Munnangi, Ketan Patel, Sandra E. Reznik

Research output: Contribution to journalArticle

Abstract

Aim: Previously, we have shown that inhibition of SphK by the SphK inhibitor-II (SKI II) prevents lipopolysaccharide-induced preterm birth in mice. The aim of this study was to develop a vaginal self-nanoemulsifying drug-delivery system (SNEDDS) for SKI II. Materials & methods: A SKI II-loaded SNEDDS was characterized and tested in a murine preterm birth model. Results: The SNEDDS immediately formed a gel and then slowly emulsified to nanoglobules with over 500-fold enhancement of SKI II solubility at vaginal pH. Intravaginal administration of the SKI II SNEDDS significantly decreased lipopolysaccharide-induced preterm birth in mice. Conclusion: A vaginal nanoformulation of SKI II represents a novel, noninvasive approach to prevent preterm birth.

Original languageEnglish (US)
Pages (from-to)2835-2851
Number of pages17
JournalNanomedicine
Volume14
Issue number21
DOIs
StatePublished - Jan 1 2019

Fingerprint

Premature Birth
Drug Delivery Systems
Lipopolysaccharides
Intravaginal Administration
Solubility
Gels

Keywords

  • inflammation
  • lipopolysaccharide
  • nanoformulation
  • preterm birth
  • SKI II
  • SNEDDS
  • sphingosine kinase inhibitor
  • vaginal administration

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Biomedical Engineering
  • Materials Science(all)

Cite this

A vaginal nanoformulation of a SphK inhibitor attenuates lipopolysaccharide-induced preterm birth in mice. / Giusto, Kiersten; Patki, Manali; Koya, Jagadish; Ashby, Charles R.; Munnangi, Swapna; Patel, Ketan; Reznik, Sandra E.

In: Nanomedicine, Vol. 14, No. 21, 01.01.2019, p. 2835-2851.

Research output: Contribution to journalArticle

Giusto, Kiersten ; Patki, Manali ; Koya, Jagadish ; Ashby, Charles R. ; Munnangi, Swapna ; Patel, Ketan ; Reznik, Sandra E. / A vaginal nanoformulation of a SphK inhibitor attenuates lipopolysaccharide-induced preterm birth in mice. In: Nanomedicine. 2019 ; Vol. 14, No. 21. pp. 2835-2851.
@article{4788f1be629141e898945da4f2940a48,
title = "A vaginal nanoformulation of a SphK inhibitor attenuates lipopolysaccharide-induced preterm birth in mice",
abstract = "Aim: Previously, we have shown that inhibition of SphK by the SphK inhibitor-II (SKI II) prevents lipopolysaccharide-induced preterm birth in mice. The aim of this study was to develop a vaginal self-nanoemulsifying drug-delivery system (SNEDDS) for SKI II. Materials & methods: A SKI II-loaded SNEDDS was characterized and tested in a murine preterm birth model. Results: The SNEDDS immediately formed a gel and then slowly emulsified to nanoglobules with over 500-fold enhancement of SKI II solubility at vaginal pH. Intravaginal administration of the SKI II SNEDDS significantly decreased lipopolysaccharide-induced preterm birth in mice. Conclusion: A vaginal nanoformulation of SKI II represents a novel, noninvasive approach to prevent preterm birth.",
keywords = "inflammation, lipopolysaccharide, nanoformulation, preterm birth, SKI II, SNEDDS, sphingosine kinase inhibitor, vaginal administration",
author = "Kiersten Giusto and Manali Patki and Jagadish Koya and Ashby, {Charles R.} and Swapna Munnangi and Ketan Patel and Reznik, {Sandra E.}",
year = "2019",
month = "1",
day = "1",
doi = "10.2217/nnm-2019-0243",
language = "English (US)",
volume = "14",
pages = "2835--2851",
journal = "Nanomedicine",
issn = "1743-5889",
publisher = "Future Medicine Ltd.",
number = "21",

}

TY - JOUR

T1 - A vaginal nanoformulation of a SphK inhibitor attenuates lipopolysaccharide-induced preterm birth in mice

AU - Giusto, Kiersten

AU - Patki, Manali

AU - Koya, Jagadish

AU - Ashby, Charles R.

AU - Munnangi, Swapna

AU - Patel, Ketan

AU - Reznik, Sandra E.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Aim: Previously, we have shown that inhibition of SphK by the SphK inhibitor-II (SKI II) prevents lipopolysaccharide-induced preterm birth in mice. The aim of this study was to develop a vaginal self-nanoemulsifying drug-delivery system (SNEDDS) for SKI II. Materials & methods: A SKI II-loaded SNEDDS was characterized and tested in a murine preterm birth model. Results: The SNEDDS immediately formed a gel and then slowly emulsified to nanoglobules with over 500-fold enhancement of SKI II solubility at vaginal pH. Intravaginal administration of the SKI II SNEDDS significantly decreased lipopolysaccharide-induced preterm birth in mice. Conclusion: A vaginal nanoformulation of SKI II represents a novel, noninvasive approach to prevent preterm birth.

AB - Aim: Previously, we have shown that inhibition of SphK by the SphK inhibitor-II (SKI II) prevents lipopolysaccharide-induced preterm birth in mice. The aim of this study was to develop a vaginal self-nanoemulsifying drug-delivery system (SNEDDS) for SKI II. Materials & methods: A SKI II-loaded SNEDDS was characterized and tested in a murine preterm birth model. Results: The SNEDDS immediately formed a gel and then slowly emulsified to nanoglobules with over 500-fold enhancement of SKI II solubility at vaginal pH. Intravaginal administration of the SKI II SNEDDS significantly decreased lipopolysaccharide-induced preterm birth in mice. Conclusion: A vaginal nanoformulation of SKI II represents a novel, noninvasive approach to prevent preterm birth.

KW - inflammation

KW - lipopolysaccharide

KW - nanoformulation

KW - preterm birth

KW - SKI II

KW - SNEDDS

KW - sphingosine kinase inhibitor

KW - vaginal administration

UR - http://www.scopus.com/inward/record.url?scp=85075920569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075920569&partnerID=8YFLogxK

U2 - 10.2217/nnm-2019-0243

DO - 10.2217/nnm-2019-0243

M3 - Article

C2 - 31793846

AN - SCOPUS:85075920569

VL - 14

SP - 2835

EP - 2851

JO - Nanomedicine

JF - Nanomedicine

SN - 1743-5889

IS - 21

ER -